Why Scott Got­tlieb, ven­ture cap­i­tal­ist, sees op­por­tu­ni­ty in an­tibi­otics

A drug de­vel­op­er in­vestor say­ing she’s very ex­cit­ed about an­tibi­otics right now is about the equiv­a­lent of a trad­er telling you in 2008 the hous­ing mar­ket looks at­trac­tive. It’s not just that al­most no new an­tibac­te­ri­als have been de­vel­oped in decades; the ones that make the mar­ket don’t stand to make a lot of mon­ey.

But when a Reuters re­porter asked ex-FDA chief Scott Got­tlieb what he was ex­cit­ed about now that he’s back in ven­ture cap­i­tal, Got­tlieb named the long-ne­glect­ed class.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER